PubMed:23894038 JSONTXT

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":60,"end":64},"obj":"gene:2064"},{"id":"T1","span":{"begin":74,"end":98},"obj":"disease:C0278488"},{"id":"T2","span":{"begin":317,"end":321},"obj":"gene:2064"},{"id":"T3","span":{"begin":331,"end":355},"obj":"disease:C0278488"},{"id":"T4","span":{"begin":317,"end":321},"obj":"gene:2064"},{"id":"T5","span":{"begin":357,"end":360},"obj":"disease:C0278488"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"},{"id":"R2","pred":"associated_with","subj":"T2","obj":"T3"},{"id":"R3","pred":"associated_with","subj":"T4","obj":"T5"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.\nBACKGROUND: Bevacizumab has consistently demonstrated improved progression-free survival (PFS) and response rate when combined with first-line chemotherapy for HER2-negative metastatic breast cancer (mBC). However, the lack of a significant overall survival (OS) difference continues to attract debate, and identification of patients deriving greatest benefit from bevacizumab remains elusive.\nPATIENTS AND METHODS: Individual patient data from three randomised phase III trials in the first-line HER2-negative mBC setting were analysed, focusing specifically on efficacy in poor-prognosis patients.\nRESULTS: The meta-analysis (n = 2447) demonstrated a PFS hazard ratio (HR) of 0.64 (95% confidence interval [CI] 0.57-0.71; median 9.2 months with bevacizumab versus 6.7 months with non-bevacizumab therapy) and response rate of 49% versus 32%, respectively. The OS HR was 0.97 (95% CI 0.86-1.08); median 26.7 versus 26.4 months, respectively. In patients with triple-negative mBC, the HRs for PFS and OS were 0.63 (95% CI 0.52-0.76) and 0.96 (95% CI 0.79-1.16), respectively. Median PFS was 8.1 months with bevacizumab versus 5.4 months with chemotherapy alone, median OS was 18.9 versus 17.5 months, respectively, and 1-year OS rates were 71% versus 65%.\nCONCLUSIONS: Bevacizumab improves efficacy, including 1-year OS rates, both overall and in subgroups of poor-prognosis patients with limited treatment options."}

{"project":"Allie","denotations":[{"id":"SS1_23894038_2_0","span":{"begin":220,"end":245},"obj":"expanded"},{"id":"SS2_23894038_2_0","span":{"begin":247,"end":250},"obj":"abbr"},{"id":"SS1_23894038_2_1","span":{"begin":331,"end":355},"obj":"expanded"},{"id":"SS2_23894038_2_1","span":{"begin":357,"end":360},"obj":"abbr"},{"id":"SS1_23894038_3_0","span":{"begin":398,"end":414},"obj":"expanded"},{"id":"SS2_23894038_3_0","span":{"begin":416,"end":418},"obj":"abbr"},{"id":"SS1_23894038_7_0","span":{"begin":814,"end":826},"obj":"expanded"},{"id":"SS2_23894038_7_0","span":{"begin":828,"end":830},"obj":"abbr"},{"id":"SS1_23894038_7_1","span":{"begin":845,"end":864},"obj":"expanded"},{"id":"SS2_23894038_7_1","span":{"begin":866,"end":868},"obj":"abbr"}],"relations":[{"id":"AE1_23894038_2_0","pred":"abbreviatedTo","subj":"SS1_23894038_2_0","obj":"SS2_23894038_2_0"},{"id":"AE1_23894038_2_1","pred":"abbreviatedTo","subj":"SS1_23894038_2_1","obj":"SS2_23894038_2_1"},{"id":"AE1_23894038_3_0","pred":"abbreviatedTo","subj":"SS1_23894038_3_0","obj":"SS2_23894038_3_0"},{"id":"AE1_23894038_7_0","pred":"abbreviatedTo","subj":"SS1_23894038_7_0","obj":"SS2_23894038_7_0"},{"id":"AE1_23894038_7_1","pred":"abbreviatedTo","subj":"SS1_23894038_7_1","obj":"SS2_23894038_7_1"}],"text":"First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.\nBACKGROUND: Bevacizumab has consistently demonstrated improved progression-free survival (PFS) and response rate when combined with first-line chemotherapy for HER2-negative metastatic breast cancer (mBC). However, the lack of a significant overall survival (OS) difference continues to attract debate, and identification of patients deriving greatest benefit from bevacizumab remains elusive.\nPATIENTS AND METHODS: Individual patient data from three randomised phase III trials in the first-line HER2-negative mBC setting were analysed, focusing specifically on efficacy in poor-prognosis patients.\nRESULTS: The meta-analysis (n = 2447) demonstrated a PFS hazard ratio (HR) of 0.64 (95% confidence interval [CI] 0.57-0.71; median 9.2 months with bevacizumab versus 6.7 months with non-bevacizumab therapy) and response rate of 49% versus 32%, respectively. The OS HR was 0.97 (95% CI 0.86-1.08); median 26.7 versus 26.4 months, respectively. In patients with triple-negative mBC, the HRs for PFS and OS were 0.63 (95% CI 0.52-0.76) and 0.96 (95% CI 0.79-1.16), respectively. Median PFS was 8.1 months with bevacizumab versus 5.4 months with chemotherapy alone, median OS was 18.9 versus 17.5 months, respectively, and 1-year OS rates were 71% versus 65%.\nCONCLUSIONS: Bevacizumab improves efficacy, including 1-year OS rates, both overall and in subgroups of poor-prognosis patients with limited treatment options."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":342,"end":355},"obj":"HP_0003002"},{"id":"T2","span":{"begin":342,"end":355},"obj":"HP_0100013"},{"id":"T3","span":{"begin":349,"end":355},"obj":"HP_0002664"}],"text":"First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.\nBACKGROUND: Bevacizumab has consistently demonstrated improved progression-free survival (PFS) and response rate when combined with first-line chemotherapy for HER2-negative metastatic breast cancer (mBC). However, the lack of a significant overall survival (OS) difference continues to attract debate, and identification of patients deriving greatest benefit from bevacizumab remains elusive.\nPATIENTS AND METHODS: Individual patient data from three randomised phase III trials in the first-line HER2-negative mBC setting were analysed, focusing specifically on efficacy in poor-prognosis patients.\nRESULTS: The meta-analysis (n = 2447) demonstrated a PFS hazard ratio (HR) of 0.64 (95% confidence interval [CI] 0.57-0.71; median 9.2 months with bevacizumab versus 6.7 months with non-bevacizumab therapy) and response rate of 49% versus 32%, respectively. The OS HR was 0.97 (95% CI 0.86-1.08); median 26.7 versus 26.4 months, respectively. In patients with triple-negative mBC, the HRs for PFS and OS were 0.63 (95% CI 0.52-0.76) and 0.96 (95% CI 0.79-1.16), respectively. Median PFS was 8.1 months with bevacizumab versus 5.4 months with chemotherapy alone, median OS was 18.9 versus 17.5 months, respectively, and 1-year OS rates were 71% versus 65%.\nCONCLUSIONS: Bevacizumab improves efficacy, including 1-year OS rates, both overall and in subgroups of poor-prognosis patients with limited treatment options."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"23894038-0#60#64#gene2064","span":{"begin":60,"end":64},"obj":"gene2064"},{"id":"23894038-0#74#98#diseaseC0278488","span":{"begin":74,"end":98},"obj":"diseaseC0278488"}],"relations":[{"id":"60#64#gene206474#98#diseaseC0278488","pred":"associated_with","subj":"23894038-0#60#64#gene2064","obj":"23894038-0#74#98#diseaseC0278488"}],"text":"First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.\nBACKGROUND: Bevacizumab has consistently demonstrated improved progression-free survival (PFS) and response rate when combined with first-line chemotherapy for HER2-negative metastatic breast cancer (mBC). However, the lack of a significant overall survival (OS) difference continues to attract debate, and identification of patients deriving greatest benefit from bevacizumab remains elusive.\nPATIENTS AND METHODS: Individual patient data from three randomised phase III trials in the first-line HER2-negative mBC setting were analysed, focusing specifically on efficacy in poor-prognosis patients.\nRESULTS: The meta-analysis (n = 2447) demonstrated a PFS hazard ratio (HR) of 0.64 (95% confidence interval [CI] 0.57-0.71; median 9.2 months with bevacizumab versus 6.7 months with non-bevacizumab therapy) and response rate of 49% versus 32%, respectively. The OS HR was 0.97 (95% CI 0.86-1.08); median 26.7 versus 26.4 months, respectively. In patients with triple-negative mBC, the HRs for PFS and OS were 0.63 (95% CI 0.52-0.76) and 0.96 (95% CI 0.79-1.16), respectively. Median PFS was 8.1 months with bevacizumab versus 5.4 months with chemotherapy alone, median OS was 18.9 versus 17.5 months, respectively, and 1-year OS rates were 71% versus 65%.\nCONCLUSIONS: Bevacizumab improves efficacy, including 1-year OS rates, both overall and in subgroups of poor-prognosis patients with limited treatment options."}